EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Verici Dx's enterprise value is £-1.83 Mil.
Verici Dx's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £-3.19 Mil. Therefore, Verici Dx's EV-to-EBITDA for today is 0.57.
The historical rank and industry rank for Verici Dx's EV-to-EBITDA or its related term are showing as below:
LSE:VRCI'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -2.81 Med: -1.51 Max: 0.57
Current: 0.57
During the past 4 years, the highest EV-to-EBITDA of Verici Dx was 0.57. The lowest was -2.81. And the median was -1.51.
LSE:VRCI's EV-to-EBITDA is ranked better than 97.39% of 115
companies
in the Medical Diagnostics & Research industry
Industry Median: 13.34
vs LSE:VRCI: 0.57
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Verici Dx EV-to-EBITDA Historical Data
The historical data trend for Verici Dx's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Verici Dx's EV-to-EBITDA
For the Diagnostics & Research subindustry, Verici Dx's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Verici Dx's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Verici Dx's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Verici Dx's EV-to-EBITDA falls into.
Verici Dx's current Enterprise Value is £-1.83 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was £-3.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Verici Dx (LSE:VRCI) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Verici Dx's share price for today is £0.0125.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Verici Dx's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was £-0.021.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of Verici Dx's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LSE:VRCI has been successfully added to your